GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

Original reporting
Published Nov 18, 2026, 3:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 3:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance — source image
Decision brief

The 30-second read

$GSKBullishMed
01

Why it matters

The FDA clearance provides hard validation for the ALKOVE-1 Phase 1/2 results, but the accelerated pathway means investors will focus on confirmatory endpoints and whether Nelkarmi can displace alectinib in first-line settings via ALKAZAR.

02

Market read

This is a direct FDA regulatory catalyst for GSK’s oncology pipeline, with the next tradable inflection tied to confirmatory survival data and first-line trial outcomes.

03

What to watch

Commercial uptake may be constrained by biomarker-defined eligibility, prior-treatment sequencing, and payer scrutiny of accelerated-label evidence versus established ALK competitors.

Relevance 7/10Novelty 3/10Timing: today, following the FDA accelerated approval decision

Background

GSK acquired the Nelkarmi asset (neladalkib) via its $10.6B Nuvalent deal and is rebuilding its oncology portfolio after prior divestments.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

GSK received FDA accelerated approval for Nelkarmi (neladalkib) in ALK-mutated NSCLC after prior ALK therapy, adding a new US commercialization catalyst.

Expected impact

Likely positive bias as traders price in incremental revenue potential, tempered by uncertainty around confirmatory endpoints and first-line positioning.

Evidence & confidence

The article is a first-time FDA clearance event for GSK’s drug, with explicit mention of accelerated pathway uncertainty and an ongoing Phase 3 first-line trial as the next key catalyst.

Market effects

Reinforces competitive intensity in ALK-positive NSCLC and highlights the value of next-generation ALK inhibitors with CNS penetration.

US regulatory approval can shift sentiment for European pharma oncology names with US commercialization exposure.

May affect global ALK NSCLC treatment sequencing expectations, especially around resistance mutation coverage and CNS activity.

Counterpoint

Accelerated approvals can underperform if confirmatory trials fail to show survival benefit, so the stock reaction may fade before ALKAZAR and confirmatory readouts.

Key entities

  • GSK

    Sponsor of Nelkarmi (neladalkib) and developer of the ALKAZAR Phase 3 first-line study.

  • FDA

    Granted accelerated clearance for Nelkarmi in ALK-mutated NSCLC after prior ALK-targeted therapy.

  • Nelkarmi (neladalkib)

    Once-daily oral next-generation ALK inhibitor with CNS penetration intent; approved under accelerated pathway.

  • ALKOVE-1

    Phase 1/2 trial supporting the accelerated approval, including response and duration metrics and intracranial activity.

  • ALKAZAR

    Phase 3 trial testing Nelkarmi as first-line therapy versus alectinib.

Related articles

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.

$GSKMed

GSK wins early FDA approval for lung cancer drug Nelkarmi

GSK received early FDA approval for its lung cancer drug Nelkarmi, based on trial data showing meaningful responses in patients with prior ALK inhibitor therapies. The drug demonstrated a 49% response rate in patients with one prior treatment and 32% in those with multiple treatments. GSK noted the approval strengthens its oncology portfolio and addresses unmet needs in ALK-positive lung cancer. As of 1010 GMT, GSK shares were down 0.08% at 1,867.50p.

$GSKHigh

GSK Wins Early FDA Nod for Nelkarmi

GSK (LON: GSK) received accelerated FDA approval for its lung cancer drug Nelkarmi (neladalkib) for ALK-positive non-small cell lung cancer. The approval, based on early trial data, came before the November 27 target date. GSK shares were down 0.16% at 1866p. The drug showed a 49% response rate in patients previously treated with alectinib. GSK also plans to acquire Nuvalent for $10.6bn.

$GSKMed

FDA Grants Accelerated Approval to Neladalkib for ALK Positive Lung Cancer

The FDA granted accelerated approval to GSK’s neladalkib (Nelkarmi) for adults with previously treated ALK-positive metastatic or locally advanced NSCLC. Based on the Phase I/II ALKOVE-1 trial, confirmed ORR was 49% (after alectinib) and 32% (after multiple ALK TKIs plus platinum), with intracranial ORR 55% and 26%. Key safety issues included hepatotoxicity (56%).